ZA200707953B - Methods and compositions for modulating hyperstabilized c-met - Google Patents

Methods and compositions for modulating hyperstabilized c-met

Info

Publication number
ZA200707953B
ZA200707953B ZA200707953A ZA200707953A ZA200707953B ZA 200707953 B ZA200707953 B ZA 200707953B ZA 200707953 A ZA200707953 A ZA 200707953A ZA 200707953 A ZA200707953 A ZA 200707953A ZA 200707953 B ZA200707953 B ZA 200707953B
Authority
ZA
South Africa
Prior art keywords
hyperstabilized
modulating
met
compositions
methods
Prior art date
Application number
ZA200707953A
Other languages
English (en)
Inventor
Kong-Beltran Monica
Dineli M Wickramasinghe
Original Assignee
Genenthech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37053941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200707953(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genenthech Inc filed Critical Genenthech Inc
Publication of ZA200707953B publication Critical patent/ZA200707953B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200707953A 2005-03-25 2006-03-24 Methods and compositions for modulating hyperstabilized c-met ZA200707953B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66548205P 2005-03-25 2005-03-25

Publications (1)

Publication Number Publication Date
ZA200707953B true ZA200707953B (en) 2009-06-24

Family

ID=37053941

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200707953A ZA200707953B (en) 2005-03-25 2006-03-24 Methods and compositions for modulating hyperstabilized c-met

Country Status (18)

Country Link
US (2) US7615529B2 (zh)
EP (1) EP1868648B1 (zh)
JP (2) JP2008535821A (zh)
KR (1) KR20080000613A (zh)
CN (1) CN101184506B (zh)
AU (1) AU2006229989B2 (zh)
BR (1) BRPI0611468A2 (zh)
CA (1) CA2599988A1 (zh)
ES (1) ES2539790T3 (zh)
HK (1) HK1109075A1 (zh)
IL (1) IL185708A (zh)
MX (1) MX2007011652A (zh)
NO (1) NO20075412L (zh)
NZ (1) NZ561211A (zh)
RU (1) RU2404193C2 (zh)
SG (1) SG159547A1 (zh)
WO (1) WO2006104911A2 (zh)
ZA (1) ZA200707953B (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615529B2 (en) * 2005-03-25 2009-11-10 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
CN102014913A (zh) * 2008-03-06 2011-04-13 健泰科生物技术公司 C-met和egfr拮抗剂的联合疗法
US20120034228A1 (en) * 2008-10-01 2012-02-09 Micromet Ag CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
KR20110124368A (ko) * 2009-04-07 2011-11-16 로슈 글리카트 아게 이중특이적 항―erbb―2/항―c―met 항체
KR20110124369A (ko) * 2009-04-07 2011-11-16 로슈 글리카트 아게 이중특이적 항­erbb­3/항­c­met 항체
UA108201C2 (xx) 2009-04-20 2015-04-10 Антитіла, специфічні для кадгерину-17
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 c-Met에 특이적으로 결합하는 항체 및 그의 용도
EP2496601B1 (en) 2009-11-05 2017-06-07 F. Hoffmann-La Roche AG Methods and composition for secretion of heterologous polypeptides
EP2545077B1 (en) 2010-03-10 2018-10-31 Genmab A/S Monoclonal antibodies against c-met
AU2011318574B2 (en) * 2010-10-20 2016-03-03 Oxford Biotherapeutics Ltd. Antibodies
SG194932A1 (en) 2011-06-30 2013-12-30 Genentech Inc Anti-c-met antibody formulations
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
EP2758430A4 (en) 2011-09-20 2015-06-03 Lilly Co Eli ANTI-C-MET ANTIBODY
WO2013049112A1 (en) * 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 c-Met의 SEMA 도메인 내의 에피토프에 특이적으로 결합하는 항체
AU2012340826A1 (en) * 2011-11-21 2014-05-29 Genentech, Inc. Purification of anti-c-met antibodies
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
ME03486B (me) 2012-10-12 2020-01-20 Medimmune Ltd Pirolobenzodiazepini i njihovi konjugati
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
JP2016510755A (ja) 2013-03-06 2016-04-11 メリマック ファーマシューティカルズ インコーポレーティッド 抗C−METタンデムFc二重特異性抗体
CN105209077B (zh) 2013-03-13 2019-06-11 麦迪穆有限责任公司 吡咯并苯并二氮杂卓以及其结合物
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
PL3116999T3 (pl) 2014-03-14 2021-12-27 F.Hoffmann-La Roche Ag Sposoby i kompozycje do wydzielania polipeptydów heterologicznych
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
IL250902B (en) 2014-09-16 2022-08-01 Symphogen As Anti-met antibodies and preparations
GB201419108D0 (en) * 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
US20180057595A1 (en) 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
IL306104A (en) 2016-09-14 2023-11-01 Abbvie Biotherapeutics Inc Antibodies against (CD27) PD-1
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドMedImmune Limited 免疫介在性療法薬を有する抗体−薬物コンジュゲート
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
MX2020012418A (es) 2018-05-23 2021-04-28 Adc Therapeutics Sa Adyuvante molecular.
CN112703004A (zh) 2018-07-15 2021-04-23 伊诺奇安生物制药公司 使用重组树突状细胞用于癌症治疗的方法和组合物
EP3931224A4 (en) 2019-02-26 2023-03-01 Janssen Biotech, Inc. COMBINATION THERAPIES AND PATIENT STRATIFICATION WITH BISPECIFIC ANTI-EGFR/C-MET ANTIBODIES
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
CN114340684A (zh) 2019-09-16 2022-04-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
CN114478788A (zh) 2020-11-11 2022-05-13 高新 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
EP0906448B1 (en) 1996-04-05 2009-02-25 Antonio Giordano Methods for the diagnosis and prognosis of cancer
CA2258153C (en) * 1996-07-03 2004-08-17 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof
AU2003230874A1 (en) * 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
BRPI0407446A (pt) 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
PL1636593T3 (pl) * 2003-06-06 2009-08-31 Genentech Inc Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met.
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AU2004298483A1 (en) * 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
EP1718677B1 (en) 2003-12-19 2012-04-18 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
US7615529B2 (en) 2005-03-25 2009-11-10 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
WO2006104912A2 (en) * 2005-03-25 2006-10-05 Genentech, Inc. C-met mutations in lung cancer

Also Published As

Publication number Publication date
AU2006229989B2 (en) 2012-02-02
NZ561211A (en) 2011-03-31
US8536118B2 (en) 2013-09-17
JP2008535821A (ja) 2008-09-04
CA2599988A1 (en) 2006-10-05
ES2539790T3 (es) 2015-07-06
IL185708A (en) 2014-11-30
JP2012232979A (ja) 2012-11-29
MX2007011652A (es) 2007-11-14
HK1109075A1 (zh) 2008-05-30
CN101184506A (zh) 2008-05-21
WO2006104911A2 (en) 2006-10-05
US20100028337A1 (en) 2010-02-04
KR20080000613A (ko) 2008-01-02
RU2007139452A (ru) 2009-04-27
SG159547A1 (en) 2010-03-30
RU2404193C2 (ru) 2010-11-20
BRPI0611468A2 (pt) 2010-09-08
US7615529B2 (en) 2009-11-10
US20060270594A1 (en) 2006-11-30
NO20075412L (no) 2007-12-21
EP1868648B1 (en) 2015-04-15
CN101184506B (zh) 2013-07-17
WO2006104911A3 (en) 2007-02-22
AU2006229989A1 (en) 2006-10-05
EP1868648A2 (en) 2007-12-26
IL185708A0 (en) 2008-01-06

Similar Documents

Publication Publication Date Title
IL185708A0 (en) Methods and compositions for modulating hyperstabilized c-met
EP1895838A4 (en) COMPOSITIONS AND METHODS
EP1930012A4 (en) COMPOSITION CONTAINING A CELLO-OLIGOSACCHARIDE
GB0522658D0 (en) Composition
HK1165444A1 (zh) 用於調整止血的組合物及方法
EP1843734A4 (en) COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS
EP1865042A4 (en) ANTI-FREEZE COMPOSITION
EP1962852A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
GB0519164D0 (en) Composition
GB0506044D0 (en) Composition
GB0508250D0 (en) Composition
EP1847249A4 (en) hair dye
GB0507167D0 (en) Composition
IL185753A0 (en) Methods and compositions for modulating vascular integrity
EP1947129A4 (en) PHOTORADIC AND PHOTOCYSTIC CURING COMPOSITION
EP1864573A4 (en) AGRICULTURAL CHEMICAL COMPOSITION
GB0501348D0 (en) Compositions and methods
GB0502341D0 (en) Composition
GB0513641D0 (en) Anti-egeing composition
EP1809761A4 (en) COMPOSITIONS AND METHODS FOR MODULATING DHR96
EP1924257A4 (en) STABILIZED 3-HYDROXYFLAVAN COMPOSITIONS AND METHOD THEREFOR
GB0510286D0 (en) Composition
GB0525968D0 (en) Compositions and methods
GB0511497D0 (en) Composition
GB0515907D0 (en) Composition